Bio-Gene Technology Equity Ratio
The Equity Ratio of Bio-Gene Technology (BGT.AX) as of Oct 11, 2026 is 80.09 %. In the previous year, Equity Ratio was 75.68 % — a change of 5.83% (higher).
Get this data via API
Financial Data API
Equity Ratio
80.09 %
YoY
5.83%
Last updated:
The Bio-Gene Technology Equity Ratio history
3 Years
10 Years
25 Years
Max
| YEAR | Equity Ratio | YoY |
|---|---|---|
| 80.09 % | +5.83% | |
| 75.68 % | -14.34% | |
| 88.34 % | +5.17% | |
| 83.99 % | -2.14% | |
| 85.83 % | +1.09% | |
| 84.91 % | -7.06% | |
| 91.36 % | +2.69% | |
| 88.97 % | -1.25% | |
| 90.09 % | -6.19% | |
| 96.04 % | +73.75% | |
| 55.28 % | -44.72% | |
| 100.00 % | +0.33% | |
| 99.67 % | — |
Bio-Gene Technology Stock analysis
Frequently Asked Questions about Bio-Gene Technology stock
Equity Ratio of Bio-Gene Technology is 80.09 % in 2026.
Equity Ratio of Bio-Gene Technology changed from 75.68 % to 80.09 %, representing a 5.83% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Equity Ratio Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.
The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Bio-Gene Technology with sector peers and the industry average to assess whether it is attractive.
Leverage — Bio-Gene Technology
All Key Metrics — Bio-Gene Technology
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth